Takaaki Kosugi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Takaaki Kosugi has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
Kazuhiko Tsuruya
Department of Nephrology, Nara Medical University
6 shared publicationsHikari Tasaki
Department of Nephrology, Nara medical University, Nara, Japan
4 shared publicationsHiroyuki Tamaki
Department of Nephrology, Nara medical University, Nara, Japan
4 shared publications- Kazuhiko Tsuruya
Department of Nephrology, Nara Medical University , Kashihara
4 shared publications - Masahiro Eriguchi
Department of Nephrology, Nara medical University, Nara, Japan
4 shared publications Ken-Ichi Samejima
Department of Nephrology, Nara Medical University
3 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by Wolters Kluwer Health in Kidney360
A Body Shape Index and Risk of Kidney Function Decline in Older Adults with CKD
Background: A Body Shape Index has recently emerged as a useful obesity marker for predicting adverse events. Although its usefulness has been reported even in older adults, who tend to exhibit the obesity paradox, little evidence is available regarding the association between A Body Shape Index and kidney outcomes. This study aimed to investigate the associations between A Body Shape Index or body mass index (BMI) and kidney outcomes in older adults with CKD. Methods: This nationwide longitudinal observational study included individuals aged 65–74 years with CKD who underwent annual health checkups between 2008 and 2014. Exposures of interest were A Body Shape Index and BMI, and the primary outcome was a 40% decline in estimated glomerular filtration rate (eGFR). The associations between quartiles (Q1–Q4) of A Body Shape Index and BMI and a 40% decline in eGFR were assessed using Cox regression analysis for each sex. Restricted cubic spline analysis was performed to investigate nonlinear associations. The eGFR trajectory across A Body Shape Index categories was evaluated using a mixed-effects model. Results: Among 31,292 men and 23,167 women with CKD, 544 men and 315 women experienced a 40% decline in eGFR during a median follow-up of 26.4 months. Compared to Q1 of A Body Shape Index, Q3 and Q4 were associated with the kidney outcome in men, with adjusted hazard ratios and 95% confidence intervals of 1.32 (1.01–1.71) and 1.72 (1.34–2.21), respectively. The rate of eGFR decline over time was also greater in these categories in men. In contrast, the association between high values of A Body Shape Index and kidney outcomes did not reach statistical significance in women. High BMI was not associated with kidney outcomes in either sex. Conclusions: Higher values of A Body Shape Index were associated with CKD progression in older men in Japan, whereas this association was less evident in women.
- 11 August 2026
- Published by Wolters Kluwer Health in Kidney360
Open AccessA Body Shape Index and Risk of Kidney Function Decline in Older Adults with CKD
Background: A Body Shape Index has recently emerged as a useful obesity marker for predicting adverse events. Although its usefulness has been reported even in older adults, who tend to exhibit the obesity paradox, little evidence is available regarding the association between A Body Shape Index and kidney outcomes. This study aimed to investigate the associations between A Body Shape Index or body mass index (BMI) and kidney outcomes in older adults with CKD. Methods: This nationwide longitudinal observational study included individuals aged 65–74 years with CKD who underwent annual health checkups between 2008 and 2014. Exposures of interest were A Body Shape Index and BMI, and the primary outcome was a 40% decline in estimated glomerular filtration rate (eGFR). The associations between quartiles (Q1–Q4) of A Body Shape Index and BMI and a 40% decline in eGFR were assessed using Cox regression analysis for each sex. Restricted cubic spline analysis was performed to investigate nonlinear associations. The eGFR trajectory across A Body Shape Index categories was evaluated using a mixed-effects model. Results: Among 31,292 men and 23,167 women with CKD, 544 men and 315 women experienced a 40% decline in eGFR during a median follow-up of 26.4 months. Compared to Q1 of A Body Shape Index, Q3 and Q4 were associated with the kidney outcome in men, with adjusted hazard ratios and 95% confidence intervals of 1.32 (1.01–1.71) and 1.72 (1.34–2.21), respectively. The rate of eGFR decline over time was also greater in these categories in men. In contrast, the association between high values of A Body Shape Index and kidney outcomes did not reach statistical significance in women. High BMI was not associated with kidney outcomes in either sex. Conclusions: Higher values of A Body Shape Index were associated with CKD progression in older men in Japan, whereas this association was less evident in women.
- Open Access
- 9 February 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1) , 2624169
SGLT2 inhibitors preserve serum chloride in non-diabetic CKD: a propensity-matched and LASSO regression analysis
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are novel renoprotective agents for patients with chronic kidney disease (CKD) and have diverse effects, including on the regulation of electrolyte balance. However, their effects on serum chloride concentrations remain unclear. We conducted a retrospective single-center study of 343 CKD patients without diabetes or proteinuria who were not taking diuretics, including 202 SGLT2i users and 141 non-users, and applied propensity score (PS) matching and LASSO regression analysis. The outcomes were the change in chloride concentration with adjustment for covariates, before and after PS matching. Factors associated with these changes were identified using multivariable analysis and LASSO regression. An adjusted linear mixed effects model showed that the annual changes in chloride concentration for the non-SGLT2i and SGLT2i users were -0.39 (95% CI: -0.61 to 0.17) mEq/L/year and 0.49 (95% CI: -0.02 to 1.00) mEq/L/year, respectively [difference 0.88 (95% CI: 0.58 to 1.17) mEq/L/year] (p < 0.001). After PS matching, there was also a significant difference between users and non-users of SGLT2is in the mean change in chloride concentration [difference 0.44 (95% CI: 0.03 to 0.84) mEq/L/year] (p = 0.036). Subgroup analyses confirmed these findings. Furthermore, the use of SGLT2is had the strongest influence on the 2-year change in serum chloride concentration. To our knowledge, this is the first propensity-matched study to demonstrate a sustained chloride-preserving effect of SGLT2 inhibitors in non-diabetic CKD. In conclusion, this study identifies a previously underrecognized tubular electrolyte effect of SGLT2 inhibitors-preservation of serum chloride-which may partly explain their consistent cardioprotective effects across diverse CKD populations.
- 9 February 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1) , 2624169
Open AccessSGLT2 inhibitors preserve serum chloride in non-diabetic CKD: a propensity-matched and LASSO regression analysis
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are novel renoprotective agents for patients with chronic kidney disease (CKD) and have diverse effects, including on the regulation of electrolyte balance. However, their effects on serum chloride concentrations remain unclear. We conducted a retrospective single-center study of 343 CKD patients without diabetes or proteinuria who were not taking diuretics, including 202 SGLT2i users and 141 non-users, and applied propensity score (PS) matching and LASSO regression analysis. The outcomes were the change in chloride concentration with adjustment for covariates, before and after PS matching. Factors associated with these changes were identified using multivariable analysis and LASSO regression. An adjusted linear mixed effects model showed that the annual changes in chloride concentration for the non-SGLT2i and SGLT2i users were -0.39 (95% CI: -0.61 to 0.17) mEq/L/year and 0.49 (95% CI: -0.02 to 1.00) mEq/L/year, respectively [difference 0.88 (95% CI: 0.58 to 1.17) mEq/L/year] (p < 0.001). After PS matching, there was also a significant difference between users and non-users of SGLT2is in the mean change in chloride concentration [difference 0.44 (95% CI: 0.03 to 0.84) mEq/L/year] (p = 0.036). Subgroup analyses confirmed these findings. Furthermore, the use of SGLT2is had the strongest influence on the 2-year change in serum chloride concentration. To our knowledge, this is the first propensity-matched study to demonstrate a sustained chloride-preserving effect of SGLT2 inhibitors in non-diabetic CKD. In conclusion, this study identifies a previously underrecognized tubular electrolyte effect of SGLT2 inhibitors-preservation of serum chloride-which may partly explain their consistent cardioprotective effects across diverse CKD populations.
- 5 January 2026
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 44 (3) , 354-362
Association between femoral localized cortical thickening (“beaking” or “flaring”) and bisphosphonate duration in glucocorticoid-induced osteoporosis
Introduction Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, and bisphosphonates (BPs) are widely used for treatment. Localized cortical thickening (LCT, “beaking” or “flaring”) is a characteristic radiographic finding and a potential precursor of atypical femoral fracture, a known complication of long-term BP use. The incidence of LCT and its association with BP duration in GIOP remain unclear. Materials and methods In this cross-sectional study, 86 outpatients with GIOP (mean age, 60.6 years; 62.8% women) were included. Femoral radiographs were evaluated for LCT, cortical thickness index (CTI; diaphyseal/subtrochanteric), and lateral bowing angle (LBA). Patients were stratified by BP duration (≥2 or ≥4 years), and 1:1 propensity score matching was used to evaluate the association with LCT. Associations of BP duration with CTI and LBA were analyzed using linear mixed-effects models; correlations with bone turnover markers (BTMs) and bone mineral density (BMD) were also examined. Results LCT was observed in 11 (12.8%) patients, including 10 undergoing BP therapy. Patients with LCT had a significantly longer duration of BP use (median: 8.0 years vs. 1.2 years, p <0.01). After matching, BP use for ≥4 years was significantly associated with LCT (odds ratio=11.29, p=0.01), whereas that for ≥2 years was not. Diaphyseal CTI significantly increased with BP duration; no associations were found with subtrochanteric CTI, LBA, BTMs, or BMD. Conclusion In GIOP, prolonged BP use, especially for ≥4 years, was associated with LCT and greater diaphyseal cortical thickness. Radiographic assessment is essential in patients with GIOP and long-term BP use.
- 5 January 2026
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 44 (3) , 354-362
Association between femoral localized cortical thickening (“beaking” or “flaring”) and bisphosphonate duration in glucocorticoid-induced osteoporosis
Introduction Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, and bisphosphonates (BPs) are widely used for treatment. Localized cortical thickening (LCT, “beaking” or “flaring”) is a characteristic radiographic finding and a potential precursor of atypical femoral fracture, a known complication of long-term BP use. The incidence of LCT and its association with BP duration in GIOP remain unclear. Materials and methods In this cross-sectional study, 86 outpatients with GIOP (mean age, 60.6 years; 62.8% women) were included. Femoral radiographs were evaluated for LCT, cortical thickness index (CTI; diaphyseal/subtrochanteric), and lateral bowing angle (LBA). Patients were stratified by BP duration (≥2 or ≥4 years), and 1:1 propensity score matching was used to evaluate the association with LCT. Associations of BP duration with CTI and LBA were analyzed using linear mixed-effects models; correlations with bone turnover markers (BTMs) and bone mineral density (BMD) were also examined. Results LCT was observed in 11 (12.8%) patients, including 10 undergoing BP therapy. Patients with LCT had a significantly longer duration of BP use (median: 8.0 years vs. 1.2 years, p <0.01). After matching, BP use for ≥4 years was significantly associated with LCT (odds ratio=11.29, p=0.01), whereas that for ≥2 years was not. Diaphyseal CTI significantly increased with BP duration; no associations were found with subtrochanteric CTI, LBA, BTMs, or BMD. Conclusion In GIOP, prolonged BP use, especially for ≥4 years, was associated with LCT and greater diaphyseal cortical thickness. Radiographic assessment is essential in patients with GIOP and long-term BP use.
- 12 December 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (4) , 615-625
The Association between Low-Grade Proteinuria and Adverse Kidney Outcomes in IgA Nephropathy
Key Points: Systematic review/meta-analysis of 23 studies (15,289 patients) quantified prognostic effect of low-grade proteinuria in IgA nephropathy. Low-grade proteinuria (0.5–1.0 g/d) linked to higher kidney risk (hazard ratio, 1.73–2.87) and faster eGFR decline (−1.02 ml/min per year). Long-term suppression below 0.5 g/d should be a key therapeutic goal, supporting current IgA nephropathy clinical guidelines. Background: Overt proteinuria (>1.0 g/d) is a well-established risk factor for kidney disease progression in IgA nephropathy. However, recent evidence suggests that even low-grade proteinuria, typically defined as 0.5–1.0 g/d, may be clinically significant. The prognostic effect of low-grade proteinuria has not been systematically evaluated. Methods: We conducted a systematic review and meta-analysis to evaluate the association between low-grade proteinuria and adverse kidney outcomes in patients with IgA nephropathy. A systematic literature search was performed on PubMed and Web of Science. Eligible studies included those reporting on kidney outcomes such as eGFR decline, kidney failure, or eGFR slope in relation to low-grade proteinuria measured either at baseline or during follow-up ( e.g ., time-averaged proteinuria). Data were synthesized using random-effects meta-analysis. The protocol was registered in the Open Science Framework REGISTRIES (https://osf.io/5dfqr). Results: A total of 23 studies ( N =15,289) met the inclusion criteria, of which 15 contributed to at least one meta-analysis. Baseline low-grade proteinuria was significantly associated with an increased risk of adverse kidney outcomes compared with proteinuria below 0.5 g/d (pooled hazard ratio, 1.73; 95% confidence interval [CI], 1.36 to 2.20; nine studies). Similarly, low-grade time-averaged proteinuria was associated with a higher risk of kidney outcomes (pooled hazard ratio, 2.87; 95% CI, 1.48 to 5.56; seven studies) and a significantly steeper annual decline in eGFR (mean difference, −1.02 ml/min per 1.73 m 2 per year; 95% CI, −1.60 to −0.45; four studies). Subgroup analyses and leave-one-out sensitivity analyses were consistent with the overall findings. Conclusions: Low-grade proteinuria, whether assessed at baseline or over time, is an important predictor of kidney disease progression in patients with IgA nephropathy. These results reinforce recent clinical guidelines recommending proteinuria control under 0.5 g/d. Long-term suppression of proteinuria should be considered a key therapeutic goal in IgA nephropathy.
- 12 December 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (4) , 615-625
The Association between Low-Grade Proteinuria and Adverse Kidney Outcomes in IgA Nephropathy
Key Points: Systematic review/meta-analysis of 23 studies (15,289 patients) quantified prognostic effect of low-grade proteinuria in IgA nephropathy. Low-grade proteinuria (0.5–1.0 g/d) linked to higher kidney risk (hazard ratio, 1.73–2.87) and faster eGFR decline (−1.02 ml/min per year). Long-term suppression below 0.5 g/d should be a key therapeutic goal, supporting current IgA nephropathy clinical guidelines. Background: Overt proteinuria (>1.0 g/d) is a well-established risk factor for kidney disease progression in IgA nephropathy. However, recent evidence suggests that even low-grade proteinuria, typically defined as 0.5–1.0 g/d, may be clinically significant. The prognostic effect of low-grade proteinuria has not been systematically evaluated. Methods: We conducted a systematic review and meta-analysis to evaluate the association between low-grade proteinuria and adverse kidney outcomes in patients with IgA nephropathy. A systematic literature search was performed on PubMed and Web of Science. Eligible studies included those reporting on kidney outcomes such as eGFR decline, kidney failure, or eGFR slope in relation to low-grade proteinuria measured either at baseline or during follow-up ( e.g ., time-averaged proteinuria). Data were synthesized using random-effects meta-analysis. The protocol was registered in the Open Science Framework REGISTRIES (https://osf.io/5dfqr). Results: A total of 23 studies ( N =15,289) met the inclusion criteria, of which 15 contributed to at least one meta-analysis. Baseline low-grade proteinuria was significantly associated with an increased risk of adverse kidney outcomes compared with proteinuria below 0.5 g/d (pooled hazard ratio, 1.73; 95% confidence interval [CI], 1.36 to 2.20; nine studies). Similarly, low-grade time-averaged proteinuria was associated with a higher risk of kidney outcomes (pooled hazard ratio, 2.87; 95% CI, 1.48 to 5.56; seven studies) and a significantly steeper annual decline in eGFR (mean difference, −1.02 ml/min per 1.73 m 2 per year; 95% CI, −1.60 to −0.45; four studies). Subgroup analyses and leave-one-out sensitivity analyses were consistent with the overall findings. Conclusions: Low-grade proteinuria, whether assessed at baseline or over time, is an important predictor of kidney disease progression in patients with IgA nephropathy. These results reinforce recent clinical guidelines recommending proteinuria control under 0.5 g/d. Long-term suppression of proteinuria should be considered a key therapeutic goal in IgA nephropathy.
- 6 November 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (2) , 201-210
Fibroblast Growth Factor 23, Urinary Phosphate, and Risk of Progression of CKD
Key Points: High intact fibroblast growth hormone 23 levels, measured by automated chemiluminescent enzyme immunoassay, were associated with composite kidney outcomes in non–dialysis-dependent CKD. The association between intact fibroblast growth hormone 23 levels and outcomes was more pronounced in patients with low 24-hour urinary phosphate excretion. Fibroblast growth hormone 23 with 24-hour urinary phosphate excretion may assist in predicting the progression of CKD. Background: Association between fibroblast growth hormone 23 (FGF23) levels and kidney outcomes and the effect of urinary phosphate excretion (UPE) on this association remain uncertain. This study aimed to investigate the association between FGF23 levels and kidney outcomes on the basis of UPE levels. Methods: This observational study included 946 patients with non–dialysis-dependent CKD at a tertiary medical center in Japan. Intact FGF23 (iFGF23) levels were measured using an automated chemiluminescent enzyme immunoassay. The association between iFGF23 levels and composite kidney failure with replacement therapy and a 40% decline in eGFR was investigated using Cox regression analysis. A nonlinear relationship was investigated using restricted cubic spline analysis. Subgroup analyses on the basis of 24-hour UPE and fractional excretion of phosphate were also performed. Results: The median eGFR level was 46 ml/min per 1.73 m 2 . During a median follow-up period of 27.2 months, 181 patients experienced composite kidney outcomes. Multivariable Cox regression analysis showed that the risk of composite kidney outcomes was higher in the highest FGF23 category of quartile 4 compared with that in a reference category of quartile 1, with a hazard ratio of 2.12 (95% confidence interval: 1.05 to 4.28). Restricted cubic spline analysis yielded consistent results. The association between high FGF23 levels and composite kidney outcomes was more pronounced in patients with low 24-hour UPE levels. However, fractional excretion of phosphate did not modify this association. Conclusions: High iFGF23 levels are associated with composite kidney outcomes in patients with non–dialysis-dependent CKD. This association was more pronounced in those with low 24-hour UPE levels.
- 6 November 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (2) , 201-210
Fibroblast Growth Factor 23, Urinary Phosphate, and Risk of Progression of CKD
Key Points: High intact fibroblast growth hormone 23 levels, measured by automated chemiluminescent enzyme immunoassay, were associated with composite kidney outcomes in non–dialysis-dependent CKD. The association between intact fibroblast growth hormone 23 levels and outcomes was more pronounced in patients with low 24-hour urinary phosphate excretion. Fibroblast growth hormone 23 with 24-hour urinary phosphate excretion may assist in predicting the progression of CKD. Background: Association between fibroblast growth hormone 23 (FGF23) levels and kidney outcomes and the effect of urinary phosphate excretion (UPE) on this association remain uncertain. This study aimed to investigate the association between FGF23 levels and kidney outcomes on the basis of UPE levels. Methods: This observational study included 946 patients with non–dialysis-dependent CKD at a tertiary medical center in Japan. Intact FGF23 (iFGF23) levels were measured using an automated chemiluminescent enzyme immunoassay. The association between iFGF23 levels and composite kidney failure with replacement therapy and a 40% decline in eGFR was investigated using Cox regression analysis. A nonlinear relationship was investigated using restricted cubic spline analysis. Subgroup analyses on the basis of 24-hour UPE and fractional excretion of phosphate were also performed. Results: The median eGFR level was 46 ml/min per 1.73 m 2 . During a median follow-up period of 27.2 months, 181 patients experienced composite kidney outcomes. Multivariable Cox regression analysis showed that the risk of composite kidney outcomes was higher in the highest FGF23 category of quartile 4 compared with that in a reference category of quartile 1, with a hazard ratio of 2.12 (95% confidence interval: 1.05 to 4.28). Restricted cubic spline analysis yielded consistent results. The association between high FGF23 levels and composite kidney outcomes was more pronounced in patients with low 24-hour UPE levels. However, fractional excretion of phosphate did not modify this association. Conclusions: High iFGF23 levels are associated with composite kidney outcomes in patients with non–dialysis-dependent CKD. This association was more pronounced in those with low 24-hour UPE levels.
- Open Access
The association between low-grade proteinuria and adverse kidney outcomes in IgA nephropathy: A systematic review and meta-analysis
Background: Overt proteinuria (>1.0 g/day) is a well-established risk factor for kidney disease progression in IgA nephropathy (IgAN). However, recent evidence suggests that even low-grade proteinuria, typically defined as 0.5–1.0 g/day, may be clinically significant. The prognostic impact of low-grade proteinuria has not been systematically evaluated. Methods: We conducted a systematic review and meta-analysis to evaluate the association between low-grade proteinuria and adverse kidney outcomes in patients with IgAN. A systematic literature search was performed on PubMed and Web of Science. Eligible studies included those reporting on kidney outcomes such as estimated glomerular filtration rate (eGFR) decline, kidney failure, or eGFR slope in relation to low-grade proteinuria measured either at baseline or during follow-up (e.g., time-averaged proteinuria [TAP]). Data were synthesized using random-effects meta-analysis. No funding was received for this review. The protocol was registered in OSF REGISTRIES [ https://osf.io/5dfqr ]. Results: A total of 23 studies involving 15,289 patients met the inclusion criteria. Baseline low-grade proteinuria was significantly associated with an increased risk of adverse kidney outcomes compared to proteinuria below 0.5 g/day (pooled hazard ratio [HR] 1.73, 95% confidence interval [CI] 1.36–2.20). Similarly, low-grade TAP was associated with a higher risk of kidney outcomes (pooled HR 2.87, 95% CI 1.48–5.56) and a significantly steeper annual decline in eGFR (mean difference −1.02 mL/min/1.73 m 2 /year, 95% CI −1.60 to −0.45). Subgroup analyses based on geographic region and leave-one-out sensitivity analyses were consistent with the overall findings. Conclusions: Low-grade proteinuria, whether assessed at baseline or over time, is an important predictor of kidney disease progression in patients with IgAN. These results reinforce recent clinical guidelines recommending proteinuria control under 0.5 g/day. Long-term suppression of proteinuria should be considered a key therapeutic goal in IgAN.
Open AccessThe association between low-grade proteinuria and adverse kidney outcomes in IgA nephropathy: A systematic review and meta-analysis
Background: Overt proteinuria (>1.0 g/day) is a well-established risk factor for kidney disease progression in IgA nephropathy (IgAN). However, recent evidence suggests that even low-grade proteinuria, typically defined as 0.5–1.0 g/day, may be clinically significant. The prognostic impact of low-grade proteinuria has not been systematically evaluated. Methods: We conducted a systematic review and meta-analysis to evaluate the association between low-grade proteinuria and adverse kidney outcomes in patients with IgAN. A systematic literature search was performed on PubMed and Web of Science. Eligible studies included those reporting on kidney outcomes such as estimated glomerular filtration rate (eGFR) decline, kidney failure, or eGFR slope in relation to low-grade proteinuria measured either at baseline or during follow-up (e.g., time-averaged proteinuria [TAP]). Data were synthesized using random-effects meta-analysis. No funding was received for this review. The protocol was registered in OSF REGISTRIES [ https://osf.io/5dfqr ]. Results: A total of 23 studies involving 15,289 patients met the inclusion criteria. Baseline low-grade proteinuria was significantly associated with an increased risk of adverse kidney outcomes compared to proteinuria below 0.5 g/day (pooled hazard ratio [HR] 1.73, 95% confidence interval [CI] 1.36–2.20). Similarly, low-grade TAP was associated with a higher risk of kidney outcomes (pooled HR 2.87, 95% CI 1.48–5.56) and a significantly steeper annual decline in eGFR (mean difference −1.02 mL/min/1.73 m 2 /year, 95% CI −1.60 to −0.45). Subgroup analyses based on geographic region and leave-one-out sensitivity analyses were consistent with the overall findings. Conclusions: Low-grade proteinuria, whether assessed at baseline or over time, is an important predictor of kidney disease progression in patients with IgAN. These results reinforce recent clinical guidelines recommending proteinuria control under 0.5 g/day. Long-term suppression of proteinuria should be considered a key therapeutic goal in IgAN.
- Open Access
- 19 June 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (11) , 1899-1905
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Lower eGFR Decline in Nondiabetic CKD Patients without Proteinuria
Key Points: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) significantly slowed chronic decline in eGFR in nondiabetic CKD patients without proteinuria. Propensity score–matched analysis confirmed that SGLT2i users had a significantly slower postinitial dip eGFR slope than nonusers. Subgroup analyses consistently supported the renoprotective effect of SGLT2is in this population. Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have shown promise as renoprotective agents, building on the success of renin-angiotensin system blockers. Although SGLT2is have been shown to slow renal deterioration in diabetic and nondiabetic CKD with proteinuria, it is unclear whether similar effects occur in nondiabetic, nonproteinuric CKD. Methods: This study used propensity score analysis to evaluate the effects of SGLT2is on changes in annual eGFR in nondiabetic CKD patients with trivial proteinuria (urinary protein–creatinine ratio 2 , and median urinary protein–creatinine ratio of 0.15 (0.09–0.29) g/gCr. Results: Adjusted linear mixed-effects models showed that while the eGFR decline over a 3-year period (total) was similar between the two groups, there was a significantly smaller decline between 3 months after baseline and 2-year follow-up (chronic) in SGLT2i users compared with nonusers, with a difference of 1.23 (95% confidence interval, 0.43 to 2.02; P = 0.002) ml/min per 1.73 m 2 per year. After propensity score matching, SGLT2i users exhibited significantly slower chronic decline than nonusers, with a difference of 1.50 (95% confidence interval, 0.63 to 2.36; P < 0.001) ml/min per 1.73 m 2 per year. Subgroup analyses confirmed these findings. Conclusions: This study suggests that SGLT2is may slow eGFR decline in non-diabetic CKD patients with trivial proteinuria, supporting the potential use of SGLT2is as renoprotective agents in this population.
- 19 June 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (11) , 1899-1905
Open AccessEffects of Sodium-Glucose Cotransporter 2 Inhibitors on Lower eGFR Decline in Nondiabetic CKD Patients without Proteinuria
Key Points: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) significantly slowed chronic decline in eGFR in nondiabetic CKD patients without proteinuria. Propensity score–matched analysis confirmed that SGLT2i users had a significantly slower postinitial dip eGFR slope than nonusers. Subgroup analyses consistently supported the renoprotective effect of SGLT2is in this population. Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have shown promise as renoprotective agents, building on the success of renin-angiotensin system blockers. Although SGLT2is have been shown to slow renal deterioration in diabetic and nondiabetic CKD with proteinuria, it is unclear whether similar effects occur in nondiabetic, nonproteinuric CKD. Methods: This study used propensity score analysis to evaluate the effects of SGLT2is on changes in annual eGFR in nondiabetic CKD patients with trivial proteinuria (urinary protein–creatinine ratio 2 , and median urinary protein–creatinine ratio of 0.15 (0.09–0.29) g/gCr. Results: Adjusted linear mixed-effects models showed that while the eGFR decline over a 3-year period (total) was similar between the two groups, there was a significantly smaller decline between 3 months after baseline and 2-year follow-up (chronic) in SGLT2i users compared with nonusers, with a difference of 1.23 (95% confidence interval, 0.43 to 2.02; P = 0.002) ml/min per 1.73 m 2 per year. After propensity score matching, SGLT2i users exhibited significantly slower chronic decline than nonusers, with a difference of 1.50 (95% confidence interval, 0.63 to 2.36; P < 0.001) ml/min per 1.73 m 2 per year. Subgroup analyses confirmed these findings. Conclusions: This study suggests that SGLT2is may slow eGFR decline in non-diabetic CKD patients with trivial proteinuria, supporting the potential use of SGLT2is as renoprotective agents in this population.
- Open Access
- 11 February 2025
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 29 (6) , 831-842
Association between hemoglobin level and mortality in patients undergoing maintenance hemodialysis: a nationwide dialysis registry in Japan
Background: The optimal hemoglobin (Hb) range in patients undergoing hemodialysis remains controversial. We aimed to investigate the association between Hb levels and mortality in patients undergoing hemodialysis and explore the potential factors modifying this association. Methods: This observational study utilized a nationwide database from the Japanese Renal Data Registry spanning from 2019 to 2021. This study included 265,779 patients undergoing hemodialysis thrice a week. The association between Hb levels and all-cause and cause-specific mortality was investigated using Cox regression analysis. The nonlinear relationship between Hb levels and outcomes was investigated using restricted cubic spline analysis. Results: During a median follow-up period of 24 months, 45,734 patients died. Compared to the reference Hb category of 10–10.9 g/dL, the risk of all-cause mortality was higher in the Hb categories of < 9.0, 9.0–9.9, and ≥ 13 g/dL with adjusted hazard ratios (95% confidence intervals) of 1.24 (1.20–1.29), 1.09 (1.06–1.12), and 1.19 (1.14–1.25), respectively. Restricted cubic spline analysis also showed a U-shaped relationship between Hb level and mortality. The subgroup analysis indicated that the Hb category of 12.0–12.9 g/dL was associated with increased mortality risk in patients with a dialysis vintage of ≥ 10 years and those with a history of cerebral infarction. Conclusion: Hb levels of < 10.0 and ≥ 13.0 g/dL were significantly associated with an increased mortality risk compared to an Hb level of 10.0–10.9 g/dL in patients undergoing hemodialysis.
- 11 February 2025
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 29 (6) , 831-842
Open AccessAssociation between hemoglobin level and mortality in patients undergoing maintenance hemodialysis: a nationwide dialysis registry in Japan
Background: The optimal hemoglobin (Hb) range in patients undergoing hemodialysis remains controversial. We aimed to investigate the association between Hb levels and mortality in patients undergoing hemodialysis and explore the potential factors modifying this association. Methods: This observational study utilized a nationwide database from the Japanese Renal Data Registry spanning from 2019 to 2021. This study included 265,779 patients undergoing hemodialysis thrice a week. The association between Hb levels and all-cause and cause-specific mortality was investigated using Cox regression analysis. The nonlinear relationship between Hb levels and outcomes was investigated using restricted cubic spline analysis. Results: During a median follow-up period of 24 months, 45,734 patients died. Compared to the reference Hb category of 10–10.9 g/dL, the risk of all-cause mortality was higher in the Hb categories of < 9.0, 9.0–9.9, and ≥ 13 g/dL with adjusted hazard ratios (95% confidence intervals) of 1.24 (1.20–1.29), 1.09 (1.06–1.12), and 1.19 (1.14–1.25), respectively. Restricted cubic spline analysis also showed a U-shaped relationship between Hb level and mortality. The subgroup analysis indicated that the Hb category of 12.0–12.9 g/dL was associated with increased mortality risk in patients with a dialysis vintage of ≥ 10 years and those with a history of cerebral infarction. Conclusion: Hb levels of < 10.0 and ≥ 13.0 g/dL were significantly associated with an increased mortality risk compared to an Hb level of 10.0–10.9 g/dL in patients undergoing hemodialysis.
- Open Access
- 24 January 2025
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 35 (3) , 443-453
Nutritional Status Modifies the Association Between Hemoglobin Level and Mortality in Older Patients Undergoing Hemodialysis: A Nationwide Dialysis Registry in Japan
- 24 January 2025
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 35 (3) , 443-453
Open AccessNutritional Status Modifies the Association Between Hemoglobin Level and Mortality in Older Patients Undergoing Hemodialysis: A Nationwide Dialysis Registry in Japan
- 2 November 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (1) , 150-161
Association of body indices with mortality in older population: Japan Specific Health Checkups (J‐ SHC ) Study
Background: Obesity indices reflect not only fat mass but also muscle mass and nutritional status in older people. Therefore, they may not accurately reflect prognosis. This study aimed to investigate associations between a body shape index (ABSI), body mass index (BMI), and mortality in the general older population. Methods: This nationwide observational longitudinal study included individuals aged between 65 and 74 years who underwent annual health checkups between 2008 and 2014. Exposures of interest were ABSI and BMI, and the primary outcome was all‐cause mortality. Association between the ABSI and BMI quartile (Q1–4) and mortality was assessed using Cox regression analysis. A restricted cubic spline was also used to investigate nonlinear associations. The missing values were imputed using multiple imputation by chained equations. Results: Among 315,215 participants, 5074 died during a median follow‐up period of 42.5 (interquartile range: 26.2–59.3) months. Compared with ABSI Q1, ABSI Q3 and Q4 were associated with increased risk of mortality, with the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) of 1.13 (1.05–1.22) and 1.23 (1.13–1.35), respectively. Compared with BMI Q3, BMI Q1 and Q2 were associated with an increased risk of mortality, with aHRs and 95% CIs of 1.51 (1.39–1.65) and 1.12 (1.03–1.22), respectively. The impacts of these indices were greater in male than in female. The heatmap of the aHR for mortality by continuous ABSI and BMI showed that higher ABSI was consistently associated with higher mortality risk regardless of BMI, and that the combination of low BMI and high ABSI was strongly associated with increased mortality risk. Conclusions: High ABSI and low BMI are additively associated with the risk of all‐cause mortality in the general older population in Japan. Combination of ABSI and BMI is useful for evaluating mortality risk in older people.
- 2 November 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (1) , 150-161
Association of body indices with mortality in older population: Japan Specific Health Checkups (J‐ SHC ) Study
Background: Obesity indices reflect not only fat mass but also muscle mass and nutritional status in older people. Therefore, they may not accurately reflect prognosis. This study aimed to investigate associations between a body shape index (ABSI), body mass index (BMI), and mortality in the general older population. Methods: This nationwide observational longitudinal study included individuals aged between 65 and 74 years who underwent annual health checkups between 2008 and 2014. Exposures of interest were ABSI and BMI, and the primary outcome was all‐cause mortality. Association between the ABSI and BMI quartile (Q1–4) and mortality was assessed using Cox regression analysis. A restricted cubic spline was also used to investigate nonlinear associations. The missing values were imputed using multiple imputation by chained equations. Results: Among 315,215 participants, 5074 died during a median follow‐up period of 42.5 (interquartile range: 26.2–59.3) months. Compared with ABSI Q1, ABSI Q3 and Q4 were associated with increased risk of mortality, with the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) of 1.13 (1.05–1.22) and 1.23 (1.13–1.35), respectively. Compared with BMI Q3, BMI Q1 and Q2 were associated with an increased risk of mortality, with aHRs and 95% CIs of 1.51 (1.39–1.65) and 1.12 (1.03–1.22), respectively. The impacts of these indices were greater in male than in female. The heatmap of the aHR for mortality by continuous ABSI and BMI showed that higher ABSI was consistently associated with higher mortality risk regardless of BMI, and that the combination of low BMI and high ABSI was strongly associated with increased mortality risk. Conclusions: High ABSI and low BMI are additively associated with the risk of all‐cause mortality in the general older population in Japan. Combination of ABSI and BMI is useful for evaluating mortality risk in older people.